Clinical trials: Sars-CoV-2 Infection
Covid19-associated ARDS, Covid19
A First-in-Human Study of AV-001 in Healthy Subjects
Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) first-in-human study in healthy subjects.
- Conditions
- Covid19-associated ARDS, Covid19, ARDS
- Trial name
- NCT04737486
- Testing
- AV-001
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vasomune Therapeutics, Inc.
Covid-19, SARS-CoV-2
A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine
This is a Phase 2/3, randomized, multicenter, double-blind, dose-response study to evaluate the safety, immunogenicity, and efficacy of UB 612 in 2 age groups, adults 18 to 59 and ≥60 years of age with or without comorbidities.
- Conditions
- Covid-19, SARS-CoV-2, Coronavirus
- Trial name
- NCT04683224
- Testing
- UB-612
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
SARS-CoV 2, COVID-19
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin in adult hospitalized patients with moderate and severe COVID-19.
- Conditions
- SARS-CoV 2, COVID-19, Coronavirus Disease 2019
- Trial name
- NCT04622865
- Testing
- Masitinib, Isoquercetin, Best Supportive Care
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- AB Science
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
COVID-19
Omega-3 Oil Use in COVID-19 Patients in Qatar
COVID-19 infection has been widely spread since December 2019 and causing many comorbidities and fatalities. The most common clinical presentation of COVID-19 patients admitted to ICUs is respiratory failure , hypoxia and acute…
- Trial name
- Omega3 (NCT04836052)
- Testing
- Omega 3 fatty acid
- Where
- Qatar
- Volunteers
- 372 people
- Sponsor
- Hamad Medical Corporation
COVID 19
Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 in Healthy Adult Subjects
- Trial name
- NCT04583228
- Testing
- HLX71
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hengenix Biotech Inc
COVID-19 Pneumonia
NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia
This is phase II study to assess the efficacy of NestaCell® (mesenchymal stem cell) to treat severe COVID-19 pneumonia.
- Trial name
- HOPE (NCT04315987)
- Testing
- NestaCell®
- Where
- 4 sites in Brazil
- Volunteers
- 90 people
- Sponsor
- Azidus Brasil
Mild to Moderate COVID-19
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate COVID-19
- Trial name
- NCT05941793
- Testing
- MBS-COV
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 135 people
- Sponsor
- Oneness Biotech Co., Ltd.
COVID-19
Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)
This is a randomized, double-blind, placebo-controlled study of camostat mesilate in ambulatory patients with confirmed COVID-19 with at least one risk factor for severe illness.
- Trial name
- NCT04583592
- Testing
- Camostat Mesilate
- Where
- 21 sites in United States
- Volunteers
- 295 people
- Sponsor
- Sagent Pharmaceuticals Inc.
COVID-19
Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia
Preliminarily investigate the safety and efficacy of two doses of hzVSF-v13 + SOC vs. placebo + SOC for the treatment of COVID-19 pneumonia.
- Trial name
- NCT04676971
- Testing
- hzVSF-v13
- Where
- 9 sites in Italy, Russia
- Volunteers
- 115 people
- Sponsor
- ImmuneMed, Inc.
COVID-19
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
This study is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of FB2001 in hospitalized patients with moderate to severe Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT05445934
- Testing
- FB2001
- Where
- 2 sites in China
- Volunteers
- 1,188 people
- Sponsor
- Frontier Biotechnologies Inc.
COVID-19
Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell)
Popular topic: A clinical trial comparing the immunogenicity of recombinant New Coronavirus vaccine (CHO cells) among people aged 3 to 17 and 18 to 59 years of age.
- Trial name
- NCT05109598
- Testing
- Recombinant new coronavirus vaccine (CHO cell)
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
SARS-CoV-2 Infection, Influenza A
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Trial name
- NCT06191393
- Testing
- Aptitude Medical Systems Metrix COVID/Flu Test
- Where
- 3 sites in United States
- Volunteers
- 614 people
- Sponsor
- Aptitude Medical Systems
Healthy Volunteers
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.
- Trial name
- NCT04679909
- Testing
- AdCOVID
- Where
- 6 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Covid19, Pneumonia, Viral
Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19
Evaluate the safety pharmacokinetics and pharmacodynamics (PK/PD)of a single dose of Kamada anti-severe acute respiratory syndrome (SARS)- CoV-2 in patients hospitalized with COVID-19 caused pneumonia
- Trial name
- NCT04550325
- Testing
- Kamada Anti-SARS-CoV-2
- Where
- 4 sites in Israel
- Volunteers
- 12 people
- Sponsor
- Kamada, Ltd.
COVID-19, Coronavirus Disease 2019
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
This is a Phase 2, proof of concept, randomized, placebo-controlled, multicenter study to evaluate the ability of LB1148 to attenuate pulmonary dysfunction associated with COVID-19 pneumonia.
- Conditions
- COVID-19, Coronavirus Disease 2019, Covid19, COVID-19 Pneumonia
- Trial name
- NCT04390217
- Testing
- LB1148
- Sponsor
- Leading BioSciences, Inc
COVID-19
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac
Study objectives: To evaluate the immunogenicity and immunity persistence and safety of recombinant novel coronavirus vaccine (CHO cells) after booster immunization in populations vaccinated with two doses of marketed novel…
- Trial name
- NCT05205096
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
SARS-CoV-2 Infection
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects.
- Trial name
- NCT05017168
- Testing
- CT-P63
- Where
- Poland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celltrion
COVID-19 Infection
Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
The purpose of this study is to determine if a CGRP receptor antagonist may potentially blunt the severe inflammatory response at the alveolar level, delaying or reversing the path towards oxygen desaturation, Acute respiratory…
- Trial name
- NCT04346615
- Testing
- Zavegepant (BHV-3500)
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Pfizer
COVID-19
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
To explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection
- Trial name
- NCT04679350
- Testing
- hzVSF-v13
- Where
- 3 sites in South Korea
- Volunteers
- 1 people
- Sponsor
- ImmuneMed, Inc.